This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.


Somavert normalises IGF-1 in a unique way1

Somavert mechanism of action

Somavert works on cell surfaces around the body, directly targeting and blocking growth hormone receptors to inhibit IGF-I production with a high predictibility1-3

Somavert can help achieve high rates of IGF-I normalisation1,3,4

Somavert IGF-1 normalisation rates at 12 weeks​​​​​​​4

Study design: 12-week, randomised, double-blind study of three different doses of pegvisomant (10mg, 15mg, and 20mg) and placebo, given subcutaneously daily, in 112 patients with acromegaly. All patients had previously been treated with surgery, radiation therapy and/or medical therapies. ​​​​​​​4

Somavert normalised serum IGF-1 levels in 97% (87 of 90) of patients with appropriate dose titration and close patient follow up​​​​​​​3

Baseline and lowest values of individual serum IGF-1 concentrations achieved in 90 patients treated for 12 months or more with daily injections. 3

The shaded area represents age adjusted normal range for IGF-1
Study design: Prospective, open-label, 18-month, multicentre extension study that assessed the effects of Somavert in 160 patents with acromegaly treated for an everage of 425 days. ​​​​​​​3

*Van der Lely 20013: 87/90 patients taking pegvisomant for 12 months or more.

100/108  (96.2%) of patients with available IGF-1 data had a normal IGF-1 concentration at any visit during pegvisomant treatment. 2/100 patients with normalised IGF-1 were administered doses of >30mg/day5
​​​​​​​The maximum licensed dose of Somavert should not exceed 30mg per day.  Please refer to the Summary of Product Characteristics before prescribing Somavert1.​​​​​

Somavert’s tumour-independent mechanism of action may explain how it can achieve IGF-1 normalisation rates of up to 97% when appropriately titrated (n=87/90)

Somavert symptom scores reduction at 6 months​​​​​​​6 

Study Design: Observational multicentre surveillance study using the Patients-assessed Acromegaly Symptoms Questionnaire (PASQ) to evaluate signs and symptoms of acromegaly. Answers are scored based on 0 (no symptoms) to 8 (severe, incapacitating symptoms), or 0 (best possible health status) to 10 (worst possible health status).​​​​​​​6

*Schreiber 2017​​​​​​​6:Of the 229 patients in the study, 94.1% of patients received doses between 10 and 30mg/day.  Five patients had 10mg every second day; 6 patients recieved more than 30mg/day. ​​​​​​​6​​​​​​​

​​​​​​​The maximum recommended dose of Somavert is 30mg/day.  Please refer to the Summary of Product Characteristics before prescribing'.​​​​​​​1

Patients on Somavert report significant reductions versus baseline in soft tissue swelling, headache, joint pain and general physical condition, and total signs and symptoms score‡1,6

Total signs and symptoms score reduction observed at 12 weeks (p<0.05, n=112).

Somavert dosing

Help find your patient's personal optimum by titrating doses 

Learn more

** This is an optional area where footnotes can live.

Track IGF-I, symptoms and co-morbidities with ACRODAT

Learn more

Contact Us

To find out more about ACRODAT, supporting your patients or to order starter kits.

Contact Us

1. Somavert Summary of Product Characteristics. Great Britain available here. Northern Ireland available here 
2. Sherlock M, et al. Medical therapy in acromegaly. Nat Rev Endocrinol 2011;7:291–300.
3. Van der Lely AJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;24;358(9295):1754–9.
4. TrainerPJ, et al. Treatment of Acromegaly with the growth hormone -receptor antagonist pegvisomant. N Engl J Med 2000; 342(16) :1171-7
5. Pfizer Data on file: PP-SOM-GBR-1104
6. Schreiber I, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study.
Eur J Endocrinol 2007;156:75–82.

PP-SOM-GBR-1122. January 2022

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?